New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
MicroRNA can help predict which breast cancer patients are more likely to see their cancer come back

MicroRNA can help predict which breast cancer patients are more likely to see their cancer come back

byAmerican College of SurgeonsCredit: Pixabay/CC0 Public DomainMicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, ac
World medicine December 17,2023
MicroRNA can help predict which breast cancer patients are more likely to see their cancer come back

MicroRNA can help predict which breast cancer patients are more likely to see their cancer come back

byAmerican College of SurgeonsCredit: Pixabay/CC0 Public DomainMicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, ac
World medicine December 17,2023
Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

by Impact JournalsExpression of lncRNA MVIH in CC tumor as compared to marginal non-tumor tissues. Credit:Genes & Cancer(2022). DOI: 10.18632/genesandcancer.224A new research paper was
Oncology December 17,2023
Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

by Impact JournalsExpression of lncRNA MVIH in CC tumor as compared to marginal non-tumor tissues. Credit:Genes & Cancer(2022). DOI: 10.18632/genesandcancer.224A new research paper was
Oncology December 17,2023
KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer

KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer

by Nanjing University School of Life SciencesGraphical abstract. Credit:Journal of Clinical Investigation(2022). DOI: 10.1172/JCI153470KRAS is one of the most frequently activated oncogene
World medicine December 17,2023
KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer

KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer

by Nanjing University School of Life SciencesGraphical abstract. Credit:Journal of Clinical Investigation(2022). DOI: 10.1172/JCI153470KRAS is one of the most frequently activated oncogene
World medicine December 17,2023
Benefits persist for lenvatinib, pembrolizumab in renal cell cancer

Benefits persist for lenvatinib, pembrolizumab in renal cell cancer

by Elana GotkineFor patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study p
World medicine December 17,2023
Benefits persist for lenvatinib, pembrolizumab in renal cell cancer

Benefits persist for lenvatinib, pembrolizumab in renal cell cancer

by Elana GotkineFor patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study p
World medicine December 17,2023
Phase II trial shows addition of durvalumab to radiation does not improve outcomes over cetuximab for HNSCC patients

Phase II trial shows addition of durvalumab to radiation does not improve outcomes over cetuximab for HNSCC patients

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-fre
World medicine December 17,2023
Phase II trial shows addition of durvalumab to radiation does not improve outcomes over cetuximab for HNSCC patients

Phase II trial shows addition of durvalumab to radiation does not improve outcomes over cetuximab for HNSCC patients

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-fre
World medicine December 17,2023
New clinical guideline on radiation therapy for IDH-mutant glioma

New clinical guideline on radiation therapy for IDH-mutant glioma

byAmerican Society for Radiation OncologyWHO 2021 classification: Adult-type diffuse glioma. Abbreviations: IDH = isocitrate dehydrogenase; WHO = World Health Organization. Credit:Practica
World medicine December 17,2023
New clinical guideline on radiation therapy for IDH-mutant glioma

New clinical guideline on radiation therapy for IDH-mutant glioma

byAmerican Society for Radiation OncologyWHO 2021 classification: Adult-type diffuse glioma. Abbreviations: IDH = isocitrate dehydrogenase; WHO = World Health Organization. Credit:Practica
World medicine December 17,2023
Ide-cel beneficial in relapsed, refractory multiple myeloma

Ide-cel beneficial in relapsed, refractory multiple myeloma

by Elana GotkineFor patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy,
World medicine December 17,2023
Ide-cel beneficial in relapsed, refractory multiple myeloma

Ide-cel beneficial in relapsed, refractory multiple myeloma

by Elana GotkineFor patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy,
World medicine December 17,2023
New driver for a rare form of liver cancer discovered

New driver for a rare form of liver cancer discovered

byGerman Cancer Research CenterCredit: CC0 Public DomainScientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem have ide
World medicine December 16,2023
New driver for a rare form of liver cancer discovered

New driver for a rare form of liver cancer discovered

byGerman Cancer Research CenterCredit: CC0 Public DomainScientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Hebrew University in Jerusalem have ide
World medicine December 16,2023
HPV-related cancers are on the rise in men

HPV-related cancers are on the rise in men

by Scott Harris,University of PennsylvaniaGraphical abstract. Credit:JCI Insight(2022). DOI: 10.1172/jci.insight.159600As a group, human papillomaviruses (HPVs) are the most common s
World medicine December 16,2023
HPV-related cancers are on the rise in men

HPV-related cancers are on the rise in men

by Scott Harris,University of PennsylvaniaGraphical abstract. Credit:JCI Insight(2022). DOI: 10.1172/jci.insight.159600As a group, human papillomaviruses (HPVs) are the most common s
World medicine December 16,2023
Fighting tumors through sugar deprivation

Fighting tumors through sugar deprivation

by Oslo University HospitalCredit: Oslo University HospitalOne of the deadliest forms of cancer is the brain tumor glioblastoma multiforme (GBM). It is a rare disease, with approximately 28,000 cases
World medicine December 16,2023
Fighting tumors through sugar deprivation

Fighting tumors through sugar deprivation

by Oslo University HospitalCredit: Oslo University HospitalOne of the deadliest forms of cancer is the brain tumor glioblastoma multiforme (GBM). It is a rare disease, with approximately 28,000 cases
World medicine December 16,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com